The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC).
Daniel M. Geynisman
No relevant relationships to disclose
Yuanyuan Zha
No relevant relationships to disclose
Rangesh Kunnavakkam
No relevant relationships to disclose
Mebea Aklilu
No relevant relationships to disclose
Daniel Virgil Thomas Catenacci
No relevant relationships to disclose
Blase N. Polite
No relevant relationships to disclose
Cara Ann Rosenbaum
No relevant relationships to disclose
Azadeh Namakydoust
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Thomas Gajewski
No relevant relationships to disclose
Hedy Lee Kindler
No relevant relationships to disclose